Michalaki Marina A, Vagenakis Apostolos G, Leonardou Aggeliki S, Argentou Marianna N, Habeos Ioannis G, Makri Maria G, Psyrogiannis Agathoklis I, Kalfarentzos Fotis E, Kyriazopoulou Venetsana E
Division of Endocrinology, Department of Medicine, University Hospital, Patras, Greece.
Thyroid. 2006 Jan;16(1):73-8. doi: 10.1089/thy.2006.16.73.
Morbidly obese subjects may present with abnormal thyroid function tests but the reported data are scarce. Therefore, we studied the thyroid parameters in 144 morbidly obese patients, 110 females and 34 males, to assess the prevalence of hypothyroidism. Eleven percent (11.8%) carried the diagnosis of hypothyroidism and were undergoing levothyroxine (LT4) replacement therapy, 7.7% had newly diagnosed subclinical hypothyroidism, 0.7% had subclinical hyperthyroidism and 7.7% were euthyroid with positive antibodies (anti-thyroid peroxidase antibodies [TPOAb]). From the 144 subjects, we selected a cohort of 78 euthyroid subjects with negative TPOAb, who did not receive LT4 replacement or suppression therapy (the experimental group) and compared them to 77 normal-weight euthyroid subjects, TPOA-negative, matched for age and gender who served as controls. The experimental group had higher serum levels of triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), and thyrotropin (TSH) compared to the control group. Serum TSH concentration was associated with fasting serum insulin levels and insulin resistance but not with serum leptin levels, body mass index (BMI), fat mass, and lean body mass. In conclusion, in morbidly obese individuals, the prevalence of overt and subclinical hypothyroidism was high (19.5%). The morbidly obese subjects have higher levels of T3, FT3, T4, and TSH, probably the result of the reset of their central thyrostat at higher level.
病态肥胖受试者可能会出现甲状腺功能检查异常,但相关报道的数据较少。因此,我们研究了144例病态肥胖患者(110例女性和34例男性)的甲状腺参数,以评估甲状腺功能减退的患病率。11%(11.8%)被诊断为甲状腺功能减退并正在接受左甲状腺素(LT4)替代治疗,7.7%为新诊断的亚临床甲状腺功能减退,0.7%为亚临床甲状腺功能亢进,7.7%甲状腺功能正常但抗体(抗甲状腺过氧化物酶抗体[TPOAb])呈阳性。从这144名受试者中,我们选取了78名TPOAb阴性、甲状腺功能正常且未接受LT4替代或抑制治疗的受试者作为实验组,并将他们与77名年龄和性别相匹配、TPOA阴性的正常体重甲状腺功能正常受试者作为对照组进行比较。与对照组相比,实验组的血清三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)和促甲状腺激素(TSH)水平更高。血清TSH浓度与空腹血清胰岛素水平和胰岛素抵抗相关,但与血清瘦素水平、体重指数(BMI)、脂肪量和去脂体重无关。总之,在病态肥胖个体中,显性和亚临床甲状腺功能减退的患病率较高(19.5%)。病态肥胖受试者的T3、FT3、T4和TSH水平较高,这可能是其中枢甲状腺调节机制在更高水平重置的结果。